Ketamine use for management of vaso-occlusive pain in pediatric sickle cell disease.
Harris EM, Vilk E, Donado C, Williams A, Heeney MM, Solodiuk J, Greco C, Archer NM.
Pediatr Blood Cancer. 2023 May. 70(5):e30254. PMID: 36861789
Links
Bibliography
Intranasal fentanyl works-Why are we not using it more to treat acute pain in sickle cell disease?
Oni MO, Archer NM.
Am J Hematol. 2023 Apr. 98(4):564-565. PMID: 36746630
Diversity, equity, and inclusion: Moving from ambition to action.
Archer NM.
Pediatr Blood Cancer. 2023 Apr. 70(4):e30197. PMID: 36651689
Patient Controlled Analgesia for Vaso-Occlusive Episodes in Children: A Retrospective Study.
Donado C, Harris EM, Heeney MM, Solodiuk JC, Greco CD, Archer NM.
J Pain Symptom Manage. 2023 Jan 11. PMID: 36641004
Does fetal hemoglobin inhibit the malarial parasite Plasmodium falciparum?
Archer NM, Pasvol G, Wilson I, Duraisingh MT.
Am J Hematol. 2022 09. 97(9):E325-E327. PMID: 35834276
Enablers and barriers to newborn screening for sickle cell disease in Africa: results from a qualitative study involving programmes in six countries.
Archer NM, Inusa B, Makani J, Nkya S, Tshilolo L, Tubman VN, McGann PT, Ambrose EE, Henrich N, Spector J, Ohene-Frempong K.
BMJ Open. 2022 03 09. 12(3):e057623. PMID: 35264367
A seat at the table: A perspective on participation of Black individuals in clinical trials.
Edwards JG, Archer NM.
Pediatr Blood Cancer. 2022 05. 69(5):e29617. PMID: 35195931
A call to start hydroxyurea by 6 months of age and before the advent of sickle cell disease complications.
Elenga N, Kayemba-Kay's S, Nacher M, Archer N.
Pediatr Blood Cancer. 2022 02. 69(2):e29423. PMID: 34818451
Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study.
Liles DK, Shah NR, Scullin B, Gordeuk VR, Smith WR, Kanter J, Achebe MM, Boccia R, Crary SE, Kraft WK, Archer N, Cataldo V, Hardesty BM, Idowu M, Desai PC, Ikeda A, Puthenveetil G, Hassell KL, Sarnaik S, Kutlar A.
Br J Haematol. 2021 11. 195(4):e150-e153. PMID: 34611900
The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies.
Kountouris P, Stephanou C, Archer N, Bonifazi F, Giannuzzi V, Kuo KHM, Maggio A, Makani J, Mañú-Pereira MDM, Michailidou K, Nkya S, Nnodu OE, Trompeter S, Tshilolo L, Wonkam A, Zilfalil BA, Inusa BPD, Kleanthous M.
Am J Hematol. 2021 11 01. 96(11):E416-E420. PMID: 34406671